Is DB09 Leading Towards A New First-Line Standard Of Care? – Drs. Krie, Mardones, & O’Dea

DESTINY-Breast11, DESTINY-Breast05 & What Comes Next – Dr. Neil Iyengar & Dr. Komal Jhaveri

Is HER2+ Metastatic Breast Cancer Curable? What Comes Next – Dr. Gregory Vidal & Dr. Nusayba Bagegni

Datopotamab Deruxtecan vs Sacituzumab Govitecan Explained – Dr. Bill Gradishar & Dr. Tiffany Traina

Is T-DXd Rewriting First-Line HER2+ Metastatic Breast Cancer? – Dr. Mark Pegram & Dr. Fengting Yan

DESTINY-Breast09 & the Future of Care – Dr. Irene Kang & Dr. Aditya Bardia

Has HER2+ First-Line Treatment Officially Changed? – Dr. Neil Iyengar & Dr. Martin Dietrich

Rethinking First-Line Metastatic HER2+ Therapy with T-DXd – Drs. Mouabbi, O’Shaughnessy & Rimawi

Rewriting Neoadjuvant & Adjuvant HER2+ Breast Cancer Strategy -Drs. Alison Conlin & Heather McArthur

New First-Line Strategies in HER2+ Metastatic Breast Cancer – Dr. Mark Pegram & Dr. Carol Tweed

Vote for Breast Friends March Madness bracket

Featured Videos

Playlist: Her2+

Playlist: HR+

Playlist: Triple Negative

Playlist: HER2 Low/Utralow

Playlist: High Risk